Inhibikase Therapeutics, Inc.
IKT
$1.68
$0.010.60%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
6/10/2026
-
TipRanks: TheFly
6/4/2026
-
The Cerbat Gem
5/16/2026
-
TipRanks Financial Blog
5/13/2026
-
TipRanks Financial Blog
5/12/2026
-
Globe Newswire
5/12/2026
-
TipRanks Financial Blog
5/1/2026
-
MarketBeat
4/7/2026
-
TipRanks Financial Blog
4/7/2026
-
The Fly
4/7/2026
-
Globe Newswire
4/7/2026
-
TipRanks Financial Blog
4/6/2026
-
MarketBeat
4/3/2026
-
Globe Newswire
4/1/2026
-
MarketBeat
3/30/2026
-
TipRanks Financial Blog
3/27/2026
-
Ticker Report
3/27/2026
-
TipRanks Financial Blog
3/27/2026
-
TipRanks Financial Blog
3/26/2026
-
Seeking Alpha - Healthcare
3/26/2026
-
Globe Newswire
3/12/2026
-
MarketBeat
3/5/2026
-
MarketBeat
3/4/2026
-
MarketBeat
3/4/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, May 12, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
302 295 3800
Address
1000 N. West Street
Wilmington, DE 19801
Wilmington, DE 19801
Country
Year Founded
Business Description
Sector
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary...
more